期刊文献+

酒石酸唑吡坦片中2种杂质的合成 被引量:1

Synthesis of Two Kinds of Impurities in Zolpidem Tartrate Tablets
下载PDF
导出
摘要 目的:设计合成酒石酸唑吡坦片中杂质Ⅰ。方法:以唑吡坦及1-溴代乙酸乙酯为起始原料,经一锅法合成得到酒石酸唑吡坦片中的杂质Ⅰ(4-(二甲胺基)-3-(6-甲基-2-对甲苯基咪唑并[1,2-a]吡啶-3-基)-4-氧代丁酸),同时杂质Ⅱ(2-羟基-N,N-二甲基-2-(6-甲基-2-对甲苯基咪唑并[1,2-a]吡啶-3-基)乙酰胺)作为副产物被合成得到。结果:成功获得酒石酸唑吡坦的两个新杂质,纯度分别为95.3%及97.2%,并经质谱和核磁共振(MS,1H NMR)进行结构确证。结论:首次合成了杂质Ⅰ及杂质Ⅱ,可为酒石酸唑吡坦质量控制和工艺优化提供参考依据。 Objective: To design and synthesize impurity Ⅰ in zolpidem tartrate tablets. Methods: Zolpidem and ethyl bromoacetate were used as the starting materials to synthesize impurity Ⅰ by a one-pot reaction,and impurity Ⅱ was obtained as a by-product.Results: The target compounds were synthesized,and characterized by MS and1 H NMR. And the purity was 95. 3% and 97. 2%,respectively. Conclusion: The impurity Ⅰ and impurity Ⅱ are synthesized for the first time,which can provide scientific information for the quality control and process optimization.
作者 马晓宁 蒋涛 李昌亮 Ma Xiaoning;Jiang Tao;Li Changliang(Hunan Institute for Drug Control,Changsha 410001,China)
出处 《中国药师》 CAS 2018年第8期1496-1497,共2页 China Pharmacist
基金 2015年湖南省食品药品监督管理局食品药品安全科技项目(编号:湘食药科G201507)
关键词 唑吡坦 杂质 合成 Zolpidem Impurities Synthesis
  • 相关文献

参考文献11

二级参考文献45

  • 1哈娜,哈力,杨习江.2种用药方案治疗阿尔茨海默病的经济学评价[J].中国药房,2011,22(14):1249-1251. 被引量:3
  • 2王守箐,张卫国,柏学东.HPLC测定盐酸特拉唑嗪片中盐酸特拉唑嗪的含量[J].中国药学杂志,2007,42(7):554-555. 被引量:4
  • 3Rhodes S,Parry P,Hanning A comparison of zolpidem and placebo on respirarion and oxygen saturation during sleep in the healrby elerly[J].Br J Clin Pharmacol,1990,30:817.
  • 4吴红,李舜伟.非苯二氮■类的镇静催眠药唑吡坦[J].中国新药杂志,1997,6(1):57-59. 被引量:15
  • 5姚树桥,杨彦春.医学心理学[M].第6版.北京.人民卫生出版社.2013,45.
  • 6Kaplan Jean-Pierre,George Pascal. Imidazo[1,2-α]pyridine derivatives and their application as pharmaceuticals[P].US 4382938,1981.
  • 7Guy R,Montigny LB,David L. Process for the preparation of imidazopyridines[P].US 4794185,1987.
  • 8FERRETFI R, GALLINELLA B, La TORRE F, et al. Direct high-performance liquid chromatography enan- tioseparation of terazosin on an immobilised poly- saccharide-based chiral stationary phase under polar organic and reversed-phase conditions [J]. J Chroma- togr A,2009,1216 (28) : 5385 - 5390.
  • 9European Pharmacopoeia Committee. European Phar-macopoeia 8.0 [ M ]. Volume I1. Strasboury, France: the Directorate for the Quality of Medicines & Health Care of the Council of Europe (EDQM), 2013: 3247 - 3249.
  • 10Van de POEL H, GUILLAUMET G, VIAUD-MASS- UARD M C. Synthesis of melatonin analogues de- rived from furo [ 2,3-b ] - and [ 2,3 -c ] pyridines by use of a palladium-copper catalyst system [ J ]. Hete- rocycles ,2002,57 ( 1 ) : 55 - 71.

共引文献49

同被引文献9

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部